Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.71 |
| ▸ | HTR1A | P08908 | 1/20 | 0.71 |
| ▸ | DRD4 | P21917 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13534443 | 1.00 | DRD2 (0.71) | DRD2HTR1ADRD4 | |
| Hydrochloric Acid SCHEMBL9528020 | 0.99 | DRD2 (0.71) | DRD2HTR1ADRD4 | |
| SCHEMBL9527393 | 0.93 | DRD2 (0.71) | DRD2HTR1ADRD4 | |
| SCHEMBL17264052 | 0.93 | DRD2 (0.71) | DRD2HTR1ADRD4 | |
| Zalospirone SCHEMBL9526873 | 0.91 | DRD2 (0.72) | DRD2HTR1ADRD4 | |
| Zalospirone SCHEMBL13532604 | 0.91 | DRD2 (0.72) | DRD2HTR1ADRD4 | |
| Zalospirone SCHEMBL3374045 | 0.91 | DRD2 (0.72) | DRD2HTR1ADRD4 | |
| Zalospirone SCHEMBL17256233 | 0.91 | DRD2 (0.72) | DRD2HTR1ADRD4 | |
| Zalospirone SCHEMBL247562 | 0.91 | DRD2 (0.72) | DRD2HTR1ADRD4 | |
| Zalospirone SCHEMBL247563 | 0.91 | DRD2 (0.72) | DRD2HTR1ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0220873-B1 | Fused bicyclic imides with psychotropic activity | AMERICAN HOME PROD (US) | 1993-11-24 | — | — | EP | claimed |
| US-4957913-A | N-((4-ARYLPIPERAZINO)ALKYL) SUBSTITTUTED | AMERICAN HOME PRODUCTS CORP. (US) | 1990-09-18 | — | — | US | claimed |
| US-4892943-A | ANTIPSYCHOTIC, ANXIOLYTIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1990-01-09 | — | — | US | claimed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-4957913-A | N-((4-ARYLPIPERAZINO)ALKYL) SUBSTITTUTED | AMERICAN HOME PRODUCTS CORP. (US) | 1990-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | DRD2 242/4885HTR1A 7/4885DRD4 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.